Skip to content
MindRank
-
MindRank secures US$52M Series B funding for AI-designed oral GLP-1 therapeutics
MindRank developed MAP as an AI-native drug discovery engine that combines computational biology, chemistry, laboratory experiments and clinical data into a single research platform.